AG真人官方

Amaze Holdings, Inc. (NYSE American: AMZE), formerly Fresh Vine Wine, filed an 8-K dated 11 July 2025 to disclose a new consulting agreement and related unregistered share issuance.

• Consulting Agreement: Signed 11 July 2025 with DNA Holdings Venture Inc. (Puerto Rico) for a 12-month term, auto-renewable for another 12 months unless cancelled on 30-days notice.
• Scope of Services: Crypto strategy & token architecture, e-commerce/Web3 integration, cross-border currency solutions, credibility/visibility support and market-making for the Company鈥檚 planned Token Generation Event.
• Consideration: Company issued 100,000 common shares to the Consultant. No cash payment disclosed.
• Unregistered Securities: Shares issued under Section 4(a)(2) and/or Rule 506(b) of Regulation D, relying on the private-offering exemption.
• Reg FD: A press release announcing the agreement was furnished as Exhibit 99.1 on 15 July 2025.
• Exhibits: 10.1 (Consulting Agreement), 99.1 (Press Release), 104 (Cover Page iXBRL file).

No financial performance metrics were provided in this filing. The transaction introduces crypto-related strategic initiatives while creating modest share dilution.

JPMorgan Chase Financial Company LLC, a wholly-owned finance subsidiary of JPMorgan Chase & Co., is offering Capped Buffered Enhanced Participation Equity Notes due July 23, 2027 linked to the MSCI EAFE庐 Index ("MXEA"). The notes are fully and unconditionally guaranteed by JPMorgan Chase & Co.

Each note has a $1,000 principal amount and pays no periodic interest. Your cash payment at maturity depends on the index performance between the trade date (鈮� Jul 21 2025) and the determination date (Jul 21 2027):

• Upside: 200% participation on any index gain, capped at a maximum settlement amount between $1,185.60 and $1,217.60 (鈮� 18.56%鈥�21.76% total return).
• Buffer: Full principal is protected if the index closes down 鈮�10% (buffer level = 90% of initial).
• Downside: If the index falls more than 10%, losses are magnified by the 1.1111脳 buffer rate; investors could lose their entire investment.

Key indicative terms include a 2.00 upside participation rate, a cap level of 109.28%鈥�110.88% of the initial index level, and no listing, call or redemption features. The estimated value at pricing will be $957.20-$967.20 per $1,000 note, below the $1,000 issue price, reflecting selling commissions (鈮�2.00%), hedging costs and structuring fees. Any secondary market price is expected to be lower than the issue price and may be provided only by JPMS, which is not obligated to make markets.

Risk highlights: credit exposure to both the issuer and guarantor; price, liquidity and valuation risks due to the unlisted nature of the notes; capped upside and leveraged downside beyond the 10% buffer; currency and non-U.S. equity exposure embedded in the MSCI EAFE庐; uncertain U.S. tax treatment; and conflicts of interest as JPMS acts as calculation agent, distributor and hedging counterparty.

Investors considering this structured product should review the full "Risk Factors" and tax discussion, evaluate the trade-off between capped upside and potential principal loss, and be prepared to hold until maturity.

JPMorgan Chase Financial Company LLC is offering $736,000 of three-year "Review Notes" that are linked, individually (not as a basket), to the Dow Jones Industrial Average, the Nasdaq-100 Index and the Russell 2000 Index. The notes are fully and unconditionally guaranteed by JPMorgan Chase & Co. They price at 100% of face value ($1,000 minimum denominations) and settle on or about 9 July 2025.

Key economic terms

• Automatic call feature: If the closing level of each index on any Review Date is 鈮� its Call Value (100% of initial), the notes are automatically redeemed for par plus a fixed Call Premium of 12.25%, 24.50% or 36.75% on the first (13 Jul 2026), second (6 Jul 2027) or final (3 Jul 2028) Review Date, respectively.
• Barrier protection: If not called, principal is protected only so long as the final level of every index is 鈮� 70% of its initial level. Should any index finish below that 70% Barrier, investors are exposed to the full downside of the worst-performing index (e.g., a 鈭�50% index return delivers only $500 per $1,000 note).
• Upside cap: Returns are limited to the fixed Call Premiums; investors do not participate in any additional index appreciation.
• No periodic coupons or dividends: the instrument is zero-coupon; investors forgo index dividends.
• Credit exposure: Payments rely on the unsecured obligations of JPMorgan Financial (issuer) and JPMorgan Chase & Co. (guarantor).
• Issue economics: Estimated value set on pricing date is $948.20 per $1,000 note, implying initial embedded costs of ~5.2% (selling commission $29.50 + structuring/hedging costs).
• Liquidity: The notes will not be listed; secondary trading, if any, will be through JPMS and likely at prices below issue price.

Illustrative payouts show: (1) early call in year 1 yields $1,122.50 per note; (2) call on final Review Date yields $1,367.50; (3) no call & indices 鈮� Barrier returns par; (4) no call & worst index at 50% of initial returns $500.

Principal risks highlighted by the issuer include:

• Potential loss of up to 100% of principal if any index breaches the Barrier at maturity.
• Limited upside relative to direct equity exposure.
• Issuer/guarantor credit risk.
• Secondary-market illiquidity and pricing below issue price.
• Estimated value below issue price due to embedded costs and internal funding rate.

Investor profile: Suited to investors comfortable with structured credit exposure to JPMorgan, who seek fixed upside of 12.25鈥�36.75% if indices stay flat or rise, while accepting the risk of significant capital loss if one index falls more than 30% by July 2028.

Oxford Square Capital Corp. (NASDAQ: OXSQ) has released its 2025 Definitive Proxy Statement ahead of the 20 August 2025 Annual Meeting at its Greenwich, CT headquarters.

• Proposals: (1) election of Barry A. Osherow as the sole Class II director (term expiring 2028); (2) ratification of PricewaterhouseCoopers LLP (PwC) as independent auditor for FY-2025.
• Board structure: five-member, staggered board; 60% classified as independent. Steven P. Novak continues as Independent Chairman.
• Ownership: Directors & officers collectively hold 6.53 million shares (8.6 % of 76.0 million outstanding). CEO Jonathan H. Cohen and affiliated entities own 3.0 %, making him the largest individual insider.
• Auditor fees: PwC audit fees declined to $947,995 in 2024 from $1.08 million in 2023; no tax or other fees were incurred.
• Compensation: Independent directors earn a base $90,000 plus committee/board chair retainers and meeting fees; no equity awards are granted.
• Governance highlights: Four fully independent committees (Audit, Valuation, Nominating & Governance, Compensation) oversee risk, valuation, and advisor oversight. The Investment Advisory Agreement with Oxford Square Management was renewed on 22 April 2025 after the board reviewed fees, performance and adviser profitability.
• Quorum & voting: record date 25 June 2025; majority of outstanding shares (38.0 million) required for a quorum. Brokers may vote only on Proposal 2.

The board unanimously recommends voting FOR both proposals. No other substantive matters are scheduled.

Form 8-K Highlights: Hyperion DeFi, Inc. (formerly Eyenovia, Inc.) filed a current report covering two principal matters: (1) departure of its Chief Operating Officer and (2) a corporate name and ticker change.

Executive departure (Item 5.02): Effective July 1, 2025, COO Bren Kern鈥檚 employment terminated in connection with a previously announced reduction-in-force. Under a Separation and Release Agreement, he will receive 12 months of base salary and up to 12 months of continued health-care benefits, conditioned upon standard release and covenant provisions. The agreement is attached as Exhibit 10.1.

Name and ticker change (Item 5.03): A Certificate of Amendment filed June 30, 2025, changed the company鈥檚 legal name from Eyenovia, Inc. to Hyperion DeFi, Inc., effective 8:00 a.m. ET on July 1, 2025. Board approval under Delaware General Corporation Law 搂242 was sufficient; no stockholder vote was required. Common shares retain the same rights and CUSIP, but the Nasdaq ticker will convert from 鈥淓YEN鈥� to 鈥淗YPD鈥� beginning July 3, 2025.

Reg FD disclosure (Item 7.01): A press release regarding the rebrand and ticker change was furnished (Exhibit 99.1) and is not deemed 鈥渇iled鈥� for Exchange Act liability.

Exhibits:

• 3.1 鈥� Certificate of Amendment (Name Change)
• 10.1 鈥� Separation and Release Agreement (COO)
• 99.1 鈥� Press Release announcing changes
• 104 鈥� Inline XBRL cover page

The filing is primarily administrative; it signals a strategic rebranding without altering share structure, while simultaneously disclosing senior management turnover that may raise continuity concerns.

On 27 June 2025, Elanco Animal Health Inc. (ELAN) disclosed in a Form 4 that Executive Vice President of U.S. Pet Health & Global Digital Transformation Rajeev A. Modi received 98.9937 deferred stock units (DSUs) at a reference price of $14.29 under the company鈥檚 Executive Deferral and Stock Match Plan. Each DSU converts into one common share or its cash equivalent upon settlement after employment ends or in a predetermined future year. The award is classified as transaction code 鈥淎,鈥� meaning it is a compensation grant rather than an open-market purchase. Modi now directly holds 6,460.6903 DSUs; no shares were sold or otherwise disposed. The grant is small鈥攚orth roughly $1.4 thousand鈥攁nd does not materially alter insider ownership or the company鈥檚 share count, but it marginally reinforces management-shareholder alignment.

Elanco Animal Health Inc. (ELAN) 鈥� Form 4 insider filing

On 27 June 2025, President & CEO Jeffrey N. Simmons acquired 193.7887 deferred stock units (DSUs) under the company鈥檚 Executive Deferral and Stock Match Plan at a reference price of $14.29. Each DSU represents the right to receive either one common share or a cash equivalent upon settlement, which occurs after employment ends or in a pre-elected future year. Following the transaction, Simmons now beneficially owns 16,849.4516 DSUs, held directly.

The filing discloses no open-market purchases or sales; the units were issued as part of a compensation-related deferral program. The size of the award鈥攚orth roughly US$2.8 thousand based on the reference price鈥攊s immaterial relative to Elanco鈥檚 market capitalisation and Simmons鈥� existing holdings, but it does incrementally increase insider ownership.

Elanco Animal Health (NYSE:ELAN) filed an 8-K reporting a First Amendment to its Receivables Loan Agreement with Rabobank. The amendment extends the accounts-receivable securitization facility鈥檚 maturity from Aug 3 2026 to Jun 26 2028, keeps Elanco as performance guarantor, Elanco SPEAR LLC as borrower, and Elanco US as servicer.

The filing is deemed a material definitive agreement (Item 1.01) and a direct financial obligation/off-balance-sheet arrangement (Item 2.03). Financial amounts were not disclosed, but the longer tenor is expected to improve liquidity and refinancing flexibility. Investors should review Exhibit 10.1 for precise covenant changes.